Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.

Jeremy H PettusDavid D'AlessioJuan Pablo FriasEric G VajdaJames D PipkinJulio RosenstockGretchen WilliamsonMiriam A ZangmeisterLin ZhiKeith B Marschke

Published in: Diabetes care (2019)

Glucagon receptor antagonism with RVT-1502 significantly lowers HbA1c and FPG, with a safety profile that supports further clinical development with longer-duration studies (NCT02851849).

Keyphrases

type diabetes
cardiovascular disease
glycemic control
combination therapy
clinical trial
metabolic syndrome
adipose tissue